In 1951 Dameshek presented the concept of chronic myeloproliferative syndromes (MPS) in cluding chronic myeloid leukemia (CML), poly cythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) .
1 This term was lim ited to forms of hematopoietic disorders, in which maturation of cells is preserved, and their natu ral course as opposed to acute leukemias is chron ic (few to several years). Dameshek's concept as sumed that these syndromes result from the dis turbances of mechanisms regulating normal he matopoiesis. The discovery of the Philadelphia (Ph) chromosome made in 1960, consisting of constant cytogenetic aberration in CML cells, the G6PD isoenzyme phenomenon analysis in heterozygotic women started by Fiałkow in the 70s of the last century, and clonogenic assays introduced simultaneously by Bradley and Met calf, confirmed that the carcinogenic mutation of multipotential stem cells lies behind MPS.
2 The World Health Organization (WHO) classification implemented in 2001, alongside the classic forms proposed by Dameshek, also included hypereosi nophilic syndrome/chronic eosinophilic leukemia (CEL) and chronic neutrophilic leukemia (CNL) to the group of MPS. 3 In the last few years the list of chronic MPS has been completed by add ing systemic mastocytosis (SM). 4 The incidence of chronic MPS is estimated at 6-9 new cases per 100 thousand annually. New cases occur most commonly between 40 and 60 years of age, occasionally under the age of 20 years. Chronic myeloproliferative diseases in the initial phase are characterized by a mild course with effective hematopoiesis and overproduction of a particular cell line and with more or less pro nounced tendency to bone marrow meta plasia in the spleen, which leads to splenomegaly. Ineffec tive hematopoiesis and the appearance of blast forms in bone marrow and peripheral blood are observed after a few or several years, and are usu ally synonymous with transformation to acute myeloid leukemia. Because of advancements in molecular bio logy, molecular indices of the major ity of these diseases have been determined in the recent years. In 1984 the BCR/ABL fusion gene, the result of translocation between the 9 and 22 chromosome (Ph chromosome) was described.
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In 1993 KIT gene mutation characteristic of SM, 6 in 2003 FIP1L1/PDGFRA fusion gene, a PBE mark er, 7 and in 2005 JAK-2 gene mutation, found in the majority of PV cases in at least half of ET and MF cases and also in about 20% of PBN cas es were characterized.
AbsTRACT
Myeloproliferative syndromes (MPS) are clonal proliferation of hematopoietic progenitor cells characterized by proliferation of 1 or a few cell lines such as granulocytic, erythroid, megakaryocytic or mastocytic. These syndromes include: chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, chronic neutrophilic leukemia and systemic mastocytosis. Diagnosis of MPS is often difficult due to need of differential diagnosis with reactive proliferation caused by primarily non-hemato logical factors. Differentiation of individual MPS forms is also difficult because of overlapping of particular clinical or laboratory adnormalities. Discovery of specific molecular aberrations in the last few years facilitates diagnostic procedures. The discovered gene mutations or their fusions are associated with production of proteins possessing tyrosine kinase properties. These discoveries resulted in the successful introduction of the targeted therapy with tyrosine kinase inhibitors in the recent years.
KEy WoRds
chronic myeloproliferative syndromes, molecular abnormalities, targeted therapy erythromelalgia, pruritus after contact with wa ter and traits of gout. The most severe complica tions of polycythemia are thrombotic and hemo r rhagic by nature as well as hypertension. The pro posal of new revised diagnostic criteria signifi cantly simplifies the diagnosis of PV. 9 According ly, 2 major diagnostic criteria must be fulfilled: hemo globin level >18.5 g/dl for men or 16.5 g/dl for women and JAK-2 gene mutation (V261F or other functionally similar), and 1 out of minor criteria, among which serum erythropoietin lev el within the reference range is crucial. When the JAK-2 gene mutation is absent 2 remaining mi nor criteria must be fulfilled, that is histo logical bone marrow bio psy assessment presenting high cellularity with marked erythroid, granulocytic and megakaryocytic line proliferation, and the demonstration of the erythroid colonies increase without the addition of erythropoietin to the cul ture in clonogenic tests. In lowrisk patients (<60 years old, with no history of thrombotic events) and with normal white blood cell and platelet counts, use of lowdose acetylsalicylic acid and repeated phlebotomy are sufficient. The cytore ductive treatment is recommended in patients aged >60 years or with a history of thrombotic events and in patients with leukocytosis >15 G/l or platelet count >1000 G/l or with massive sple nomegaly. Hydroxycarbamide (1000-2000 mg/d) is most often used. Interferon α is an alterna tive in younger patients (3 million units 3 times a week). 11, 13 Essential thrombocythemia In over 50% of pa tients the onset of ET is asymptomatic and the disease is diagnosed on the basis of blood cell count analysis and increased platelet count. In some patients symptoms resulting from throm bosis or bleedings are observed. Erythromelalgia is relatively commonly noted. In diagnostic man agement first of all secondary causes of thrombo cytosis, that is infections, inflammatory diseases, sideropenias and neoplastic diseases should be ex cluded. The proposed new diagnostic criteria for ET decrease the required platelet count from 600 to 450 G/l.
9 Such a change enables early diagno sis of the disease. The next criterion of diagnos tic importance is JAK-2 gene mutation (V617F), ob served in about 50% of patients. Until very re cently it has been believed that mutation of this gene may be observed at codon 617 only; how ever, the recent publications indicate the possi bility of different gene mutations, especially at exon 12. More over, in some of the ET cases (5 10%) MPL gene mutation is observed (W515L). The third important criterion is histo logical bone marrow evaluation, presenting megakaryocytic proliferations without proliferation of erythroid and granulocytic lines. When the JAK-2 mutation is absent, exclusion of the BCR/ABL fusion gene is important. The WHO criteria do not consider CRP level, which if remains within the reference range releases the diagnostician from the duty of seeking causes of secondary thrombocythosis.
properties, responsible for proliferation of partic ular cell lines. Thus, in the majority of these dis eases a molecular marker facilitating diagnostics has been described. The proposed new WHO cri teria, issued in August 2008, use molecular cri teria to a large measure. 9 According to new WHO classification proposals, based on the assumption that molecular aberrations are an irrefutable ar gument that hematopoiesis in these syndromes is oncogenic, it is postulated to substitute the term "myeloproliferative syndromes", proposed by Dameshek, with "myeloproliferative cancers". Pro posed changes in diagnostic algorithms concern most of all PV, ET and MF, and stress the signifi cance of JAK2 gene mutation analysis and histo logical evaluation of the bone marrow bio psy. Be sides the diagnostic utility, known molecular ab errations, resulting in translation of proteins pos sessing properties of tyrosine kinases, provided a breakthrough in the therapy of these diseases. Known tyrosine kinases became a target for rap idly developing targeted therapy. From the begin ning of the 21st century a new drug, imatinib, ef fective in CML and CEL therapy, is available. Sec ond generation inhibitors of tyrosine kinases, in cluding dasatanib and nilotinib, have been intro duced in 2007. Other drugs are being evaluated in clinical trials. These drugs inhibit BCR/ABL, PDGFR and KIT tyrosine kinases.
Chronic myeloid leukemia The incidence of CML is 1-1.5 new cases per 100,000 people annually. The majority of cases are diagnosed on the basis of the routine blood cell counts in asymptomatic pa tients. The remaining patients present to the phy sician with symptoms resulting from splenomeg aly. White blood cell counts at the diagnosis per sist usually in the range of 30-100 G/l. The diag nosis has to be confirmed by the presence of Ph chromosome or BCR/ABL transcript using poly poly merase chain reaction (PCR) technique. In the case of high leukocytosis the cytoreductive treat ment with hydroxyurea is started. If leukocytosis <50 G/l is observed, the treatment with BCR/ABL tyrosine kinase inhibitor -imatinib in a dose of 400 mg/d (1 tablet in the morning) is initiated. Treatment should lead to complete cytogenetic remission (observed in >80% of patients). The molecular response is also awaited. In the case of primary or secondary resistance a drug dose can be increased to 600-800 mg or switched to sec ond generation tyrosine kinase inhibitors -dasa tanib or nilotinib. Such patients should be moni tored with cytogenetic tests and PCR. In young er patients who have a compatible bone marrow donor allogeneic bone marrow transplantation should be considered. 11, 12 Polycythemia vera PV is diagnosed in asymptom atic patients during the routine blood cell count analysis or, more commonly, on the basis of skin and mucous membrane redness or splenomega ly. Symptoms suggestive of polycythemia involve headaches and drowsiness, vision disturbances, Chronic eosinophilic leukemia Only in about 10% of patients diagnosis is made accidentally on the basis of blood morphology analysis, the remaining patients usually come to a physician with symptoms of fatigue, fever, cough, muscular pain and diarrhoea. Eosinophilic infiltrations in the heart muscle, skin, lungs and the nervous sys tem cause specific clinical symptoms. Persistent hypereosinophilia in peripheral blood >1.5 G/l is fundamental for diagnosis. All possible causes of reactive hypereosinophilia, secondary to aller gic diseases, para sitic diseases, connective tissue diseases (collagen diseases), neoplastic diseases (especially Tcell lymphomas), Hodgkin's lym phoma and other myeloproliferative diseases, in which eosinophilic cells are part of the carcino genic clone (CML, acutemyeloid type M4 with eo sirophilia leukemia, PV, NS, MF) should be exclud ed to make a diagnosis. The most important cri terion confirming diagnosis of CEL leukemia is detection of the FIP1L1/PDGFRA fusion gene. In this situation imatinib in a dose of 100 mg/d is the therapy of choice (with excellent therapeutic effect). CEL can also be diagnosed in patients with hypereosinophilia when blast cells in peripheral blood (≥2%) or in the bone marrow (≥5%) are ob served; however, blast count cannot exceed 20%. In the remaining cases, once all causes of reactive eosinophilia are excluded, idiopathic hypereosino philia is diagnosed. Now the use of the term hy pereosinophilic syndrome is not recommended. Treatment begins with corticosteroids adminis tration, and when no therapeutic response is ob tained cytoreductive treatment (hydroxycarbam ide in a dose of 1.5-2 g) is used. 16, 17 Chronic neutrophilic leukemia CNL is a very rare myeloproliferative disease, characterized by per sistent neutrophilia in peripheral blood and sple nomegaly. The Ph chromosome and the BCR/ABL fusion gene are not observed. Diagnosis is made by exclusion of other causes of neutrophilic leu kocytosis. In 20% of patients JAK-2 gene muta tion have been discovered. systemic mastocytosis The hemato logical pic ture rarely indicates this diagnosis, because the majority of mast cells mature outside the bone marrow -in the liver, spleen, lymphatic nodes and perivascular tissue. The majority of symp toms result from the release of mediators (his tamine). They include abdominal pains, bron chospasm, headaches and erythema. Skin symp toms, e.g. urticaria and pruritus, and bone symp toms, like bone pain, arthralgias and bone frac tures are also observed. Physical examination shows splenomegaly . The main diagnostic cri terion is accumulation and aggregates of masto cytes (>15 cells) in the bone marrow. Minor cri teria are: atypia of at least 85% of mast cells and found in 80% of patients KIT gene mutation at codon 816 (D816V), rarely at other codons, e.g. 522 (F522C). The remaining minor criteria are co expression of CD117, CD2 and CD25 antigens on If JAK-2 gene mutation is diagnosed, the hemo globin level with iron and ferritine levels should be analyzed in order to exclude PV. Myelofibrosis is exclud ed on the basis of histo logical evaluation of the bone marrow without fibrosis. Cytoreduc tive treatment is indicated in highrisk patients. Each of the following criteria allows use of hy droxyurea (usually in a dose of 1000-1500 mg/d): age >60 years, occurrence of thrombotic or hemo rrhagic incidents in a history and platelet count >1500 G/l or >1000 G/l in case of risk of cardio vascular complications. In younger patients and in those who do not response to hydroxyurea, anagrelid in a dose of 1.5-3.0 mg/d or inter feron α should be considered.
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Myelofibrosis In about 30% of patients with myelofibrosis the diagnosis is made on the basis of the results of blood cell counts without deter mined symptoms. In over half of patients symp toms of splenomegaly make MF diagnosis easier; in the remaining patients the following diseases influence the clinical presentation: anemia, sple nomegaly and traits of neutropenia or thrombo cytopenia associated with progressing bone mar row fibrosis or features of extramedullary meta plasia in various organs. According to the cur rent WHO proposals the histo logical bone mar row bio psy revealing proliferation and atypia of megakaryocytes, accompanied by fibrosis is the key diagnostic criterion.
9 The second criterion is JAK-2 or MPL gene mutation, and in case of its absence -exclusion of BCR/ABL mutation. De finitive MF diagnosis requires the fulfillment of at least 2 from among 4 minor criteria: the leu koerythroblastic reaction in peripheral blood, in creased lactate dehydrogenase level, anemia and palpable spleen on physical examination. Age >60 years, hemo globin level <10 g/dl, platelet count <100 G/l and >3% blast cells in the peripheral blood sample are recognized as a poor prognostic factor. In this situation allogeneic hematopoietic cell transplantation considering the socalled re duced conditioning is the strongest recommend ed management. The latest reports indicate about 58% survival within 3 years following such man agement and the transplantationrelated mortali ty about 32%. In the last few years MF therapy has been attempted with thalidomide. The response to such treatment is observed in the form of im provement in para meters of red blood cells and platelets and a decrease in spleen size. In the pro liferation phase of MF use of hydroxyurea is rec ommended. Reports on the effect of the action of new molecules inhibiting the mutated JAK-2 gene have been published recently. Clinical trials involve most of all patients with MF with JAK-2 mutation. Results of these trials are still under way. It is too early to discuss the effectiveness of these drugs and possible side or undesirable ef fects, in particular. In the center of other impor tant signalling pathways is JAK-2 kinase. More over, these drugs may also influence the nonmu tated JAK-2 gene product.
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mastocytes and increased serum tryptase levels (>20 ng/ml). Diagnosis can be confirmed if a pa tient fulfils the major criterion and 1 out of 4 mi nor criteria, or 3 out of 4 minor criteria. 4 Anti histamines are used in symptomatic therapy and in the prophylaxis. Dasatanib appeared to be an effective drug in patients with KIT D 816V gene mutation. Imatinib is the drug of choice in other KIT gene mutations (i.e. F522C). Cladribine, hy droxycarbamide or αinterferon are used in the absence of the mutation. 18, 19 In about 10-15% of patients suspected of MPS it is not feasible to make a specific diagnosis on the basis of the present criteria. This is usual ly observed in the initial phase of one of the de scribed here forms of MPS. At that time molec ular tests will be helpful, but when JAK-2 gene mutation is present, differentiation between PV, ET or MF might still be a challenge. Further fol lowup could be of help. The other cause of diag nostic problems can be establishment of the di agnosis in the late stage of the disease, in which there is bone marrow fibrosis or acceleration or blastic phase.
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